Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Cyclophosphamide in Severe Autoimmune Hematologic Disease
NCT00010387Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Mar 1999
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), Felty's syndrome (FS) and 2 more, sponsored by Johns Hopkins University. Primary endpoints: Response Rate and Event-Free Survival at 1 year. Started Mar 1999; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
autoimmune hemolytic anemia (AIHA)immune thrombocytopenia (ITP)Felty's syndrome (FS)Autoimmune neutropenia (AIN)large granular lymphocyte leukemia
Beyond the preview
Go deeper on NCT00010387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00010387.